BioArctic
BioArctic is getting closer to producing a drug that substantially limits the development of Alzheimer’s.
Scibase
SciBase improves the reliability of malignant melanoma diagnoses. The technique is used by skin doctors to support decision-making as an alternative to biopsies in cases of suspected skin cancer.
Encare
The introduction of ERAS Society surgical guidelines results in reduced time spent in hospital and improved patient outcomes. The methods, which are being promoted by the company EnCare, have improved care provision in some 23 countries. One of the people behind the initiative was once a young surgeon at Karolinska University Hospital, critical of the status quo.
Aprea Therapeutics
Aprea Therapeutics AB is working on the development of a new p53-based treatment for cancer. Klas Wiman is one of the company’s founders, and he draws a clear distinction between the roles of researcher and entrepreneur.
Extroducer
Staffan Holmin has developed a microcatheter that delivers drugs and cells directly to the body’s organs via blood vessels. The next step is to take samples from organs that are hard or too risky to reach with other methods. The key to success is an interdisciplinary team with a variety of core skill sets.
Cellaviva/Nextcell Pharma
Biobank Cellaviva offers parents-to-be the chance to store stem cells from umbilical cord blood and tissue at birth. Experiences from stem cell management have now led to the development of one of Sweden’s first cell therapy drug treatments.
Döbra
The DöBra (“Die Well” ) cards help people to reflect on and talk about their values and preferences for the end of life—a topic that can often be difficult to raise. This tool was developed through an interdisciplinary research programme at Karolinska Institutet and Umeå University, and has contributed to an ongoing process to develop support for social innovations at Karolinska Institutet.
Biolamina
Family business BioLamina has a unique technology for growing stem cells. It is an area that is currently experiencing strong growth and now the company is scaling up production.
Chundsell Medical
He is behind a unique test to distinguish benign prostate cancer from aggressive forms of the condition that require immediate treatment. Finding the right contacts at the right time was key to the success of the project.
Curosurf
The Curosurf story is a tale of success. To date, the drug has saved the lives of around one million premature babies worldwide. And the story is far from over. Despite being 73, Tore Curstedt returns to the lab every day - the lab where he has developed a new variant of a drug that is set to help many more babies in the future.
